Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai Sanyou Medical Co., Ltd. (688085.SS)
Shanghai, CN
Headquartered in Shanghai, China, Shanghai Sanyou Medical Co., Ltd. focuses on the entire lifecycle of orthopedic implants, from their initial research and development through manufacturing and ultimately sales within the Chinese market. The company distributes its medical devices under the Tytus and Sanyou brand names, primarily specializing in spinal and trauma-related implants. Its spinal product line features a broad selection, including anterior cervical plates, anterior and posterior thoracolumbar systems, posterior cervical solutions, and z-minimally invasive products. For trauma injuries, Sanyou Medical offers implant systems designed for various anatomical regions, such as the shoulder and elbow, hip and pelvis, knee, and palm and wrist.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.54% | -14.56% | -13.45% | -34.04% | -17.91% | -15.04% | -7.99% | -39.10% | -44.73% | -38.24% | -38.24% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+19.7% ★ Q1'26: +6.1% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+355.6% ★ Q1'26: -49.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-4.4% Q1'26: -20.4% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+10.3% ★ Q1'26: +0.9% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+3.3% ★ Q1'26: +0.2% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+21.1% Q1'26: +8.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.65× ★ Q1'26: 8.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
390.43M
est: 395.50M (-1.3%)
|
593.36M
est: 593.00M (+0.1%)
|
649.15M
est: 874.00M (-25.7%)
|
460.39M
est: 440.00M (+4.6%)
|
453.60M
est: 458.00M (-1.0%)
|
542.79M
est: 599.00M (-9.4%)
|
677.33M
677.33M – 677.33M
+13.1% YoY
|
835.00M
835.00M – 835.00M
+23.3% YoY
|
1.02B
1.02B – 1.02B
+21.6% YoY
|
| EBITDA |
147.03M
est: 137.73M (+6.8%)
|
230.68M
est: 206.51M (+11.7%)
|
255.09M
est: 304.37M (-16.2%)
|
161.17M
est: 153.23M (+5.2%)
|
54.70M
est: 129.29M (-57.7%)
|
86.32M
est: 169.09M (-48.9%)
|
191.20M
191.20M – 191.20M
+13.1% YoY
|
235.71M
235.71M – 235.71M
+23.3% YoY
|
286.52M
286.52M – 286.52M
+21.6% YoY
|
| EBIT |
136.99M
est: 113.97M (+20.2%)
|
217.49M
est: 170.89M (+27.3%)
|
239.74M
est: 251.86M (-4.8%)
|
135.36M
est: 126.80M (+6.8%)
|
24.43M
est: 108.73M (-77.5%)
|
56.06M
est: 142.20M (-60.6%)
|
160.80M
160.80M – 160.80M
+13.1% YoY
|
198.23M
198.23M – 198.23M
+23.3% YoY
|
240.96M
240.96M – 240.96M
+21.6% YoY
|
| Net Income |
118.56M
est: 105.53M (+12.4%)
|
186.37M
est: 169.96M (+9.7%)
|
190.82M
est: 193.12M (-1.2%)
|
95.58M
est: 85.88M (+11.3%)
|
11.47M
est: 27.76M (-58.7%)
|
63.29M
est: 89.94M (-29.6%)
|
106.59M
106.59M – 106.59M
+18.5% YoY
|
154.34M
154.34M – 154.34M
+44.8% YoY
|
206.52M
206.52M – 206.52M
+33.8% YoY
|
| SGA |
205.42M
est: 166.79M (+23.2%)
|
323.13M
est: 250.08M (+29.2%)
|
333.64M
est: 368.58M (-9.5%)
|
193.48M
est: 185.55M (+4.3%)
|
211.71M
est: 200.78M (+5.4%)
|
133.75M
est: 262.59M (-49.1%)
|
296.93M
296.93M – 296.93M
+13.1% YoY
|
366.05M
366.05M – 366.05M
+23.3% YoY
|
444.96M
444.96M – 444.96M
+21.6% YoY
|
| EPS |
0.43
est: 0.39 (+10.5%)
|
0.63
est: 0.63 (+0.5%)
|
0.64
est: 0.71 (-10.1%)
|
0.32
est: 0.32 (+1.1%)
|
0.04
est: 0.08 (-50.0%)
|
0.19
est: 0.27 (-29.6%)
|
0.32
0.32 – 0.32
+18.5% YoY
|
0.46
0.46 – 0.46
+44.8% YoY
|
0.62
0.62 – 0.62
+33.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mingyan Liu | Chairman & Chief Scientist | — | — |
| Nong Xu | GM & Director | — | male |
| Nuan Ni | Chief Financial Officer & Accounting Supervisor | — | female |
| Xianglong Fan | Director, Deputy GM & Board Secretary | — | male |
| Xiaoyi Zheng | Deputy GM, Chief Operating Officer & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688085.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
